Bristol Myers Squibb To Present Data From Over 50 Oncology Studies At ESMO Congress 2025, Covering Over 10 Cancer Types Across Pipeline and Portfolio

Author: Benzinga Newsdesk | October 13, 2025 07:01am

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from October 17-21 in Berlin, Germany. Data from more than 50 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 10 cancer types.

Key data to be presented by Bristol Myers Squibb and its collaboratorsat ESMO include:

• First disclosure of results from a global Phase 1 study of izalontamab brengitecan (iza-bren; BL-B01D1), a potential first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic non–small cell lung cancer (NSCLC) and other solid tumors (mini oral presentation); results from this trial supported the FDA's Breakthrough Therapy designation for iza-bren for patients with previously treated advanced EGFR-mutated NSCLC
• Late-breaking updates of progression-free survival (PFS) and the first disclosure of overall survival (OS) from CheckMate -8HW evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) versus Opdivo or investigator's choice of chemotherapy in first- and all-line settings in MSI-H/dMMR metastatic colorectal cancer (mCRC; Proffered paper, oral)
• Five-year follow-up of disease-free survival (DFS), overall survival (OS) and circulating tumor DNA (ctDNA) results from CheckMate -274 evaluating the adjuvant use of Opdivo in adult patients with high-risk muscle-invasive urothelial carcinoma after radical resection (MIUC; proffered paper, oral)
• Nine-year final analysis of the CheckMate -238 study of adjuvant Opdivo versus Yervoy in patients with resected advanced melanoma (mini-oral presentation)
   

Posted In: BMY